← The record

Glycomacropeptide Formula With Docosahexaenoic Acid And Low Phenylalanine

Recommended MetabolicRestrictedNot applicable line

Dietary management of phenylketonuria (PKU).

1
Submissions
1 resub
2019–19
On the record
ICER range
Cost-min
Cost basis

Decisions on record

2 decisions
  • Meeting Mar 2026 Recommended Phenylketonuria (PKU)
  • Meeting Mar 2024 Withdrawn Phenylketonuria (PKU) no PSD

Access path

1 submission · public record
  1. Jul 2019
    Recommended

    vs PKU Glytactin RTD 10

  2. PBS listing · Restricted
RecommendedDeferredNot recommended

From the public summary

Verbatim · PSD text · may span indications
PBAC outcome
6.1 The PBAC agreed with the listing of the glycomacropeptide formula, PKU GMPro® LQ, for the dietary management of phenylketonuria (PKU) processed by the Secretariat.PSD · Jul 2019
The PBAC advised that the pricing of the previously recommended powder and new liquid formulations should be set at the same cost per gram of protein equivalent (PE).PSD · Jul 2019
Consumer comments
4.2 The PBAC noted there were no consumer comments received for this item. Comparison with similar productsPSD · Jul 2019

Cost-effectiveness

Cost-minimisation analysis; no ICER calculated by design.

The PBAC noted it had recommended the powder formulation of PKU GMPro on a cost minimisation basis with PKU Glytactin RTD 10 at the same cost per gram of PE. PBAC · 2019
Cost-effectiveness accepted

Decision context

PopulationPatients with phenylketonuria (PKU) requiring dietary management via oral liquid glycomacropeptide formula.

Submission history

1 entries
DecidedOutcomeComparatorICEREvidence
Jul 2019 Recommended PKU Glytactin RTD 10 Cost-minimisation · Cost-minimisation

Similar precedents

By decision profile

Regulatory · TGA

Label narrower than PBS population — PBAC restricts to patients requiring oral liquid glycomacropeptide formula; TGA label permits any dietary management approach.